Novavax, Inc. cash flow to debt ratio of -98.32% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Novavax, Inc.'s free cash flow has decreased 149.40% from $-100.32M last year to $-250.19M, signaling decreasing performance

Novavax, Inc.'s debt to equity ratio is -2.04, signaling that the company spent its equity and risk bankruptcy.

Novavax, Inc.'s debt to equity ratio is -2.04, signaling that the company spent its equity and risk bankruptcy.

Novavax, Inc. has a net debt to EBITDA ratio of 0.02x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Novavax, Inc.'s interest coverage ratio is -5.60, which means that the company struggles to meet interest obligations, signaling financial risk.

Novavax, Inc.'s profit margin has increased (-46.41%) in the last year from -27.49% to -14.73%, signaling increasing performance

Novavax, Inc.'s short-term assets of $978.28M exceed its short-term liabilities of $459.95M

Novavax, Inc.'s return on assets of -8.42% is lower than the 5.00% threshold, indicating inefficient asset utilization

Novavax, Inc.'s return on equity of 89.73%, is higher than 15.00%, indicating good performance

Novavax, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Novavax, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings

Novavax, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Novavax, Inc. has negative free cash flow, indicating cash burn

Novavax, Inc.'s yearly earnings has increased -334.83% since last year from $-187.50M to $440.30M, signaling increasing performance

Novavax, Inc.'s yearly revenue has increased 64.69% since last year from $682.16M to $1.12G, signaling increasing performance

ROIC -9.50% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Novavax, Inc.'s 3-year revenue CAGR of -11.10% is negative, indicating declining revenue over the past 3 years

Novavax, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Novavax, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Novavax, Inc. has insufficient data to evaluate this check.

Novavax, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Novavax, Inc. is undervalued relative to its fair value price of 21.11 based on EBITDA multiple model

Novavax, Inc. has an EV/EBITDA ratio of 2.83x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Novavax, Inc. is overvalued relative to its fair value price of -50.65 based on Earnings Fair Value model

Novavax, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Novavax, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Novavax, Inc. has a price-to-sales ratio of 2.31x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue